Phyllis Foxworth serves as the Manager of Advocacy for the Huntington’s Disease Society of America (HDSA) and directs the organization’s national advocacy strategy to improve the lives of everyone affected by Huntington’s disease (HD) and their families. Ms. Foxworth mobilizes the community of volunteer advocates to raise the profile of HD with federal regulators and congressional members to speed the innovation of new therapeutic interventions, increase access to care, and reduce the financial burden on HD families.
Before joining HDSA, Ms. Foxworth directed advocacy for the Depression and Bipolar Support Alliance. She is a co-author of nine research papers focused on the financial impact of care, preferred treatment outcomes for people living with major depressive disorder, and shared decision-making and was a co-principal investigator on three PCORI projects. She has served as a patient representative panelist at several FDA public meetings and directed the first externally-led patient-focused drug development meeting that focused on mental health. Ms. Foxworth served as a patient representative for the Institute for Clinical and Economic Review during the assessment of Esketamine and served on a committee funded by the Centers for Medicare and Medicaid Services to propose an instrument for mental health value-based reimbursement.
